Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study-Reference-Cited by-同舟云学术

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study

Published:2020-04-02 Issue:4 Volume:15 Page:e0230846
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Barrero Francisco^ORCID,Mallada-Frechin Javier,Martínez-Ginés María Luisa,Marzo María Eugenia,Meca-Lallana Virginia,Izquierdo Guillermo,Ara José Ramón,Oreja-Guevara Celia,Meca-Lallana José,Forero Lucía^ORCID,Sánchez-Vera Irene,Moreno María José^ORCID,

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference29 articles.

1. Multiple sclerosis is primarily a neurodegenerative disease;A Chaudhuri;J Neural Transm (Vienna),2013

2. Multiple sclerosis: an immune or neurodegenerative disorder?;BD Trapp;Annu Rev Neurosci,2008

3. Fingolimod: a review of its use in relapsing-remitting multiple sclerosis;M Sanford;Drugs,2014

4. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis;JA Cohen;Ann Neurol,2011

5. The direct effects of fingolimod in the central nervous system: Implications for relapsing multiple sclerosis;SF Hunter;CNS Drugs,2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fingolimod real life experience in non-naive multiple sclerosis patients;The European Research Journal;2024-09-04

2. Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting;Multiple Sclerosis and Related Disorders;2023-09

3. A decade of fingolimod in multiple sclerosis: Insights from a large real-world cohort study;Revue Neurologique;2023-06

4. A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod;Advances in Therapy;2023-03-10

5. The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary;PLOS ONE;2022-04-22